Publications by authors named "Fernando Rivero-Crespo"
Article Synopsis
- A study found that using Quantitative Flow Ratio (QFR) for virtual angioplasty before and after PCI (Percutaneous Coronary Intervention) led to better outcomes than traditional angiographic methods, but there is a lack of correlation between pre-PCI QFR and post-PCI FFR (Fractional Flow Reserve).
- The study involved 84 patients with significant coronary lesions, focusing on measuring various flow ratios before and after the procedure, with an average age of 65.5 years and a majority having lesions in the left anterior descending artery.
- Despite achieving procedural success and improvements in post-PCI FFR, the pre-PCI QFR did not show reliable correlation with the post-PCI FFR, indicating
Article Synopsis
- This article reports on the annual activities of the Interventional Cardiology Association of the Spanish Society of Cardiology for 2022.
- A total of 111 centers participated, revealing a 4.8% increase in diagnostic studies and a significant 22% rise in PCIs on the left main coronary artery, while the overall PCI numbers remained stable.
- Key trends included a preference for the radial approach in 94.9% of cases, increased use of drug-eluting balloons and intracoronary imaging, and a continuous rise in noncoronary procedures, especially those related to heart valve and structural heart issues.
Coronary flow reserve (CFR) is a well-validated flow-based physiological parameter that has shown value in clinical risk stratification. CFR can be invasively assessed, classically by Doppler and, more recently, by thermodilution with saline boluses (CFR). Alternatively, continuous thermodilution is a novel operator-independent, highly-reproducible technique to invasively quantify maximum absolute coronary flow (AF).
View Article and Find Full Text PDFTIOMAX: A Spanish Multicenter Registry of the real-world use of the TItanium OptiMAX biostent: TIOMAX: Registro Español Multicéntrico Del Biostent De Titanio OptiMAX En La Vida Real.
Catheter Cardiovasc Interv
August 2018
Objectives: To compare the safety and efficacy of the new cobalt-chromium bioactive stent Titan Optimax (Hexacath, France) with its predecessor, Titan-2 .
Background: The TIOMAX registry includes 784 patients who underwent percutaneous coronary intervention with these stents in 21 Spanish hospitals.
Methods: Analysis of all patients in the registry without exclusion criteria, candidates for revascularization (March-2013/July-2014).
Objectives: We performed a post hoc analysis of outcome in patients with, versus those without, calcified target lesions from the BASE ACS trial.
Background: The outcome of contemporary stent implantation in patients with calcified lesions presenting with acute coronary syndrome is unknown.
Methods: The BASE ACS trial randomized 827 patients (1:1) presenting with acute coronary syndrome to receive either titanium-nitride-oxide-coated stents or everolimus-eluting stents.
Background: The BASE ACS randomized trial demonstrated non-inferiority of titanium-nitride-oxide-coated bioactive stents (BAS), compared with everolimus-eluting stents (EES), for the primary endpoint of major adverse cardiac events (MACE) in patients presenting with acute coronary syndrome (ACS) at 12-month follow-up. We report the final long-term clinical outcome of the trial.
Methods: We randomly assigned 827 patients with ACS to receive either BAS (417) or EES (410).
Objectives: The BASE-ACS trial demonstrated non-inferiority of titanium-nitride-oxide-coated bioactive stents (BAS), versus everolimus-eluting stents (EES), for major adverse cardiac events (MACE) at 1- and 2-year follow-up, in patients with acute coronary syndrome (ACS). We presented the 4-year outcome of the BASE-ACS trial.
Design: We randomized 827 patients with ACS to receive either BAS (417) or EES (410).
Dual Antiplatelet Therapy for 6 Months vs 12 Months After New-generation Drug-eluting Stent Implantation: Matched Analysis of ESTROFA-DAPT and ESTROFA-2.
Rev Esp Cardiol (Engl Ed)
October 2015
Introduction And Objectives: The recommendation for dual antiplatelet therapy following drug-eluting stent implantation ranges from 6 months to 12 months or beyond. Recent trials have suggested the safety of a 6-month dual antiplatelet therapy regimen, yet certain caveats to these studies limit the applicability of this shorter duration dual antiplatelet therapy strategy in real world settings.
Methods: A registry was constructed with consecutive recruitment of patients undergoing new-generation drug-eluting stent implantation and prescribed 6 months of dual antiplatelet therapy.
Stent-oriented versus patient-oriented outcome in patients undergoing early percutaneous coronary intervention for acute coronary syndrome: 2-year report from the BASE-ACS trial.
Ann Med
November 2013
Background: The BASE-ACS trial demonstrated an outcome of the titanium-nitride-oxide-coated bioactive stents (BAS) statistically non-inferior to that of the everolimus-eluting stents (EES) at 12-month follow-up in patients presenting with acute coronary syndrome (ACS). We performed a post hoc analysis of the BASE-ACS trial with particular focus on stent-oriented versus patient-oriented outcome at 24-month follow-up.
Methods: A total of 827 patients with ACS were randomly assigned to receive either BAS (417) or EES (410).
Aims: Titanium-nitride-oxide-coated bioactive stents (BAS) have demonstrated a favourable outcome when compared with paclitaxel-eluting stents in patients with acute myocardial infarction (MI). In a prospective randomised non-inferiority study design, we compared the safety and efficacy of BAS versus everolimus-eluting stents (EES) in patients with acute coronary syndrome (ACS).
Methods And Results: We randomised 827 patients with ACS (1:1) to either BAS (417) or EES (410).